Cord Blood Banking and Transplantation in a National Program: Thirteen Years of Experience.
Adolescent
Adult
Aged
Blood Banks
/ statistics & numerical data
Bone Marrow Failure Disorders
/ epidemiology
Child
Child, Preschool
Cord Blood Stem Cell Transplantation
/ standards
Disease-Free Survival
Female
Fetal Blood
Hematopoietic Stem Cell Transplantation
/ standards
History, 21st Century
Humans
Infant
Infant, Newborn
Leukemia
/ epidemiology
Male
Mexico
/ epidemiology
Middle Aged
National Health Programs
/ organization & administration
Pregnancy
Retrospective Studies
Survival Rate
Young Adult
Blood Banking
/ methods
Cord blood banking
Cord blood transplantation
Leukemia
Marrow failure
Mexico
Journal
Archives of medical research
ISSN: 1873-5487
Titre abrégé: Arch Med Res
Pays: United States
ID NLM: 9312706
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
01
07
2019
revised:
25
10
2019
accepted:
06
12
2019
pubmed:
23
2
2020
medline:
28
7
2020
entrez:
23
2
2020
Statut:
ppublish
Résumé
The umbilical cord blood bank at the Mexican Institute of Social Security (IMSS-CBB) was established in January 2005. This lead to the development of the UCB transplantation program. Herein, we describe the experience generated during these 13 years. Donor selection, as well as UCB collection, processing, and banking were performed under good manufacturing practices and standard operating procedures. UCB units were thawed, processed, and released for transplantation based on HLA and nucleated cell content. From January 2005-December 2017, 1,298 UCB units were banked; 164 of them were released for transplantation, and 118 UCB transplants were performed. Ninety-four transplants were performed in pediatric patients and 24 in adults. Sixty percent of them corresponded to patients with leukemia, 19% were patients with marrow failure, and the rest had immunodeficiency, hemoglobinopathy, metabolic disorders, or solid tumors. Engraftment was observed in 67 patients (57% of transplanted patients) and 64% of them were still alive when writing this article. In contrast, only 13 of the 51 (25%) non-engrafting patients were alive. At the time of writing this article, the disease-free survival rate was 37%, and the overall survival rate was 47%, with survival periods of 161-3,721 days. The IMSS UCB banking and transplantation program has had a significant impact for many IMSS patients. The hematopoietic transplantation program at our institution has benefited from the use of UCB as a source of transplantable cells.
Sections du résumé
BACKGROUND
The umbilical cord blood bank at the Mexican Institute of Social Security (IMSS-CBB) was established in January 2005. This lead to the development of the UCB transplantation program. Herein, we describe the experience generated during these 13 years.
STUDY DESIGN AND METHODS
Donor selection, as well as UCB collection, processing, and banking were performed under good manufacturing practices and standard operating procedures. UCB units were thawed, processed, and released for transplantation based on HLA and nucleated cell content.
RESULTS
From January 2005-December 2017, 1,298 UCB units were banked; 164 of them were released for transplantation, and 118 UCB transplants were performed. Ninety-four transplants were performed in pediatric patients and 24 in adults. Sixty percent of them corresponded to patients with leukemia, 19% were patients with marrow failure, and the rest had immunodeficiency, hemoglobinopathy, metabolic disorders, or solid tumors. Engraftment was observed in 67 patients (57% of transplanted patients) and 64% of them were still alive when writing this article. In contrast, only 13 of the 51 (25%) non-engrafting patients were alive. At the time of writing this article, the disease-free survival rate was 37%, and the overall survival rate was 47%, with survival periods of 161-3,721 days.
CONCLUSION
The IMSS UCB banking and transplantation program has had a significant impact for many IMSS patients. The hematopoietic transplantation program at our institution has benefited from the use of UCB as a source of transplantable cells.
Identifiants
pubmed: 32086109
pii: S0188-4409(19)30670-8
doi: 10.1016/j.arcmed.2019.12.006
pii:
doi:
Types de publication
Historical Article
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
54-62Informations de copyright
Copyright © 2019 IMSS. Published by Elsevier Inc. All rights reserved.